Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome.
Canet-Hermida J, Marín F, Dorca E, Dueñas N, Costas L, Salinas M, Velasco À, Peremiquel-Trillas P, Paytubi S, Ponce J, Fernández S, Martínez JM, Cárdenas L, Taltavull A, Alemany L, Meléndez C, Oliveras G, Vidal A, Capellá G, López-Bonet E, Brunet J, Matias-Guiu X, Pineda M. Canet-Hermida J, et al. Among authors: lopez bonet e. Mod Pathol. 2023 Jul;36(7):100158. doi: 10.1016/j.modpat.2023.100158. Epub 2023 Mar 12. Mod Pathol. 2023. PMID: 36918055
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.
Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA. Lopez-Bonet E, et al. J Clin Med. 2019 Dec 11;8(12):2180. doi: 10.3390/jcm8122180. J Clin Med. 2019. PMID: 31835708 Free PMC article.
Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.
Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA. Bosch-Barrera J, et al. Among authors: lopez bonet e. Cancers (Basel). 2021 Aug 19;13(16):4168. doi: 10.3390/cancers13164168. Cancers (Basel). 2021. PMID: 34439322 Free PMC article.
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041. Epub 2010 May 12. Biochem Biophys Res Commun. 2010. PMID: 20470755
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA. Oliveras-Ferraros C, et al. Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9. doi: 10.1016/j.bbrc.2011.03.039. Epub 2011 Mar 21. Biochem Biophys Res Commun. 2011. PMID: 21402055
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Int J Oncol. 2011 Dec;39(6):1455-79. doi: 10.3892/ijo.2011.1155. Epub 2011 Aug 9. Int J Oncol. 2011. PMID: 21833472
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.
Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA. Cuyàs E, et al. Among authors: lopez bonet e. Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019. Front Oncol. 2019. PMID: 30984619 Free PMC article.
51 results